following an abbreviated submission:
risankizumab (Skyrizi®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Risankizumab offers an additional treatment choice in the therapeutic class of interleukin inhibitors.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice275KB (PDF)
Medicine details
- Medicine name:
- risankizumab (Skyrizi)
- SMC ID:
- SMC2686
- Indication:
Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 13 January 2025